(Total Views: 265)
Posted On: 07/10/2019 12:09:44 PM
Post# of 36566
Also from today...
"NGIO will house both Kiromic and Antigen Express, Inc., which is developing AE37 in combination with Merck’s Keytruda for the treatment of triple negative breast cancer. Together, the broad technology portfolio and deep pipeline opportunities provided in the merger position NuGenerex Immuno-Oncology on the forefront of cancer immunotherapy. Generex has identified a vehicle to accomplish the public spin-out of NGIO, and will provide updates as the Kiromic acquisition and spin-out plans are finalized."
Would be nice to see who that is? Although if it is just "identified" right now, they may still be negotiating it.
"NGIO will house both Kiromic and Antigen Express, Inc., which is developing AE37 in combination with Merck’s Keytruda for the treatment of triple negative breast cancer. Together, the broad technology portfolio and deep pipeline opportunities provided in the merger position NuGenerex Immuno-Oncology on the forefront of cancer immunotherapy. Generex has identified a vehicle to accomplish the public spin-out of NGIO, and will provide updates as the Kiromic acquisition and spin-out plans are finalized."
Would be nice to see who that is? Although if it is just "identified" right now, they may still be negotiating it.
(0)
(0)
Disclaimer: Of course, all of this is my opinion and you should not make any investment decisions based on my opinion. I have not received any non-public information.
